Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Dermatologic 1

Conditions

Melanoma 5Carcinoma, Non-Small-Cell Lung 4Skin Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Colonic Neoplasms 2Carcinoma, Merkel Cell 2Zollinger-Ellison Syndrome 1Waldenstrom Macroglobulinemia 1Vipoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Sezary Syndrome 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Mycosis Fungoides 1

Interventions

veliparib 1Temozolomide 1Rose Bengal 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1Dacarbazine 1Capecitabine 1Bortezomib 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × Capecitabine × Dermatologic × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡